Manufacturer of Controlled Substances; Notice of Registration, 48980 [05-16568]
Download as PDF
<![CDATA[
48980
Federal Register / Vol. 70, No. 161 / Monday, August 22, 2005 / Notices
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
Schedules I and II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 25, 2004,
Navinta LLC, 1499 Lower Ferry Road,
Ewing, New Jersey 08616–1414, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic class of
controlled substances listed in Schedule
II:
Drug
a bulk manufacturer of the basic class of
controlled substances listed in Schedule
II.
Drug
Cocaine (9041) .........................
Benzoylecgonine (9180) ...........
Schedule
Lysergic Acid Diethylamide
(7315) ....................................
Tetrahydrocannabinol (7370) ...
Alphamethadol (9605) ..............
Phencyclidine (7471) ................
Benzoylecgonine (9180) ...........
Methadone (9250) ....................
Morphine (9300) .......................
I
I
I
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
Fentanyl (9801) ........................
II substances for use in diagnostic
Sufentanil (9740) ......................
II products.
No comments or objections have been
received. DEA has considered the
The company plans to bulk
factors in 21 U.S.C. 823(a) and
manufacture the controlled substances
for product development of generic and determined that the registration of
Roche Diagnostics Operations Inc. to
brand pharmaceutical products.
Any other such applicant and any
manufacture the listed basic classes of
person who is presently registered with
controlled substances is consistent with
DEA to manufacture such a substance
the public interest at this time. DEA has
may file comments or objections to the
investigated Roche Diagnostics
issuance of the proposed registration
Operations Inc. to ensure that the
pursuant to 21 CFR 1301.33(a).
company’s registration is consistent
Any such written comments or
with the public interest. The
objections being sent via regular mail
investigation has included inspection
may be addressed, in quintuplicate, to
and testing of the company’s physical
the Deputy Assistant Administrator,
security systems, verification of the
Office of Diversion Control, Drug
company’s compliance with state and
Enforcement Administration,
local laws, and a review of the
Washington, DC 20537, Attention: DEA
company’s background and history.
Federal Register Representative, Liaison Therefore, pursuant to 21 U.S.C. 823,
and Policy Section (ODL); or any being
and in accordance with 21 CFR 1301.33,
sent via express mail should be sent to
the above named company is granted
DEA Headquarters, Attention: DEA
registration as a bulk manufacturer of
Federal Register Representative/ODL,
the basic classes of controlled
2401 Jefferson-Davis Highway,
substances listed.
Alexandria, Virginia 22301; and must be
Dated: August 15, 2005.
filed no later than October 21, 2005.
Drug
Schedule
Dated: August 15, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–16567 Filed 8–19–05; 8:45 am]
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–16568 Filed 8–19–05; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Manufacturer of Controlled
Substances; Notice of Registration
By notice dated April 25, 2005, and
published in the Federal Register on
May 2, 2005, (70 FR 22704), Roche
Diagnostics Operations Inc., Attn:
Regulatory Compliance, 9115 Hague
Road, Indianapolis, Indiana 46250,
VerDate jul<14>2003
16:09 Aug 19, 2005
Jkt 205001
By notice dated March 29, 2005, and
published in the Federal Register on
April 5 2005 (70 FR 17263), Stepan
Company, Natural Products Dept., 100
W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Stepan Company to manufacture the
listed basic class of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Stepan Company to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substances
listed.
Dated: August 15, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–16566 Filed 8–19–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By notice dated March 29, 2005, and
published in the Federal Register on
April 6, 2005, (70 FR 17474–17475),
Varian, Inc., Lake Forest, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic class of controlled substances
listed in Schedule II:
Drug
Phencyclidine (7471) ................
1-Piperidinocyclohexanecarbonitrile (8603) .................
Benzoylecgonine (9180) ...........
E:\FR\FM\22AUN1.SGM
22AUN1
Schedule
II
II
II
]]>Agencies
[Federal Register Volume 70, Number 161 (Monday, August 22, 2005)]
[Notices]
[Page 48980]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16568]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By notice dated April 25, 2005, and published in the Federal
Register on May 2, 2005, (70 FR 22704), Roche Diagnostics Operations
Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis,
Indiana 46250, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315).......................... I
Tetrahydrocannabinol (7370)................................ I
Alphamethadol (9605)....................................... I
Phencyclidine (7471)....................................... II
Benzoylecgonine (9180)..................................... II
Methadone (9250)........................................... II
Morphine (9300)............................................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances for use in diagnostic products.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Roche Diagnostics Operations Inc. to manufacture the listed basic
classes of controlled substances is consistent with the public interest
at this time. DEA has investigated Roche Diagnostics Operations Inc. to
ensure that the company's registration is consistent with the public
interest. The investigation has included inspection and testing of the
company's physical security systems, verification of the company's
compliance with state and local laws, and a review of the company's
background and history. Therefore, pursuant to 21 U.S.C. 823, and in
accordance with 21 CFR 1301.33, the above named company is granted
registration as a bulk manufacturer of the basic classes of controlled
substances listed.
Dated: August 15, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-16568 Filed 8-19-05; 8:45 am]
BILLING CODE 4410-09-P
